Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.